Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]
News [12650]
Articles [175]
Editorials [5]
Conferences [248]
elearning [17]
Updates in prostate cancer from ESMO 2022
Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik
Updates in prostate cancer from ESMO 2022 ( Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik )
12 Sep 2022
Latest in mRCC from ESMO 2022
Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane...
Latest in mRCC from ESMO 2022 ( Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Oudard )
12 Sep 2022
Ideal duration of androgen deprivation therapy with post-operative radiotherapy...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )
12 Sep 2022
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
Dr Silvia Novello - University of Turin, Turin, Italy
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Fruquintinib provides improvement in overall survival for refractory mCRC
Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA
Fruquintinib provides improvement in overall survival for refractory mCRC ( Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA )
12 Sep 2022
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
12 Sep 2022
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non...
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )
12 Sep 2022
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Emerging systemic therapies in rare urothelial cancer variants
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
Emerging systemic therapies in rare urothelial cancer variants ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Lenvatinib plus pembro for aRCC - update on the CLEAR study
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
Lenvatinib plus pembro for aRCC - update on the CLEAR study ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim...
Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation